Nextrast, Inc. is a biotechnology company that is developing novel contrasting agents for taking medical images of the bowel and vasculature. Normal CT scan contrasting agents provide ambiguous images of the bowel. Nextrast is deveoping a silicon-based, orally-adminstered contrasting agent which, when used in conjunction with traditional contrast agents, delivers sharp and unambiguous images of the bowel and vasculature in a single CT pass. This reduces potential radiation exposure as well as equip doctors with a vital tool for when bowel and vasculature imaging is needed. Nextrast's technology was developed by its founders at the University of California San Francisco.
